Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversitat Jaume I
About this trial
The aim of this study is to develop and test the efficacy of first-of-its-kind, fully instrumented sensor-based smartphone-guided in-vivo exposure therapy using a just-in-time intervention for anxiety disorder. The main hypotheses are:
1. Both treatment conditions (CBT treatment with IVE and CBT treatment with IVE+SYMPTOMS-JIT) will show efficacy and no statistically significant differences will be found between them. The efficacy will be determined for the differences in pre-post treatment in the used outcome measures. 2. The therapeutic gains obtained in both treatment conditions (IVE and (IVE+SYMPTOMS-JIT) will be maintained at 1-, 6-, and 12-month follow-up periods. 3. Both treatment conditions will be efficient, that is, they will be well-valued by patients and therapists. However, IVE+SYMPTOMS-JIT will be preferred and perceived as less aversive than IVE. 4. The main barriers for the use of this technology are not technological, but rather attitudinal and they can be identified through qualitative studies.
Eligibility criteria
Qualifiers
Being at least 18 years or older.
Meeting DSM-5 diagnostic criteria (APA, 2013) for anxiety disorder, specifically specific phobia, agoraphobia, panic disorder and social phobia.
Being willing to follow the study conditions.
Sign the consent form.
Disqualifiers
Having another psychological problem that requires immediate attention.
Having current alcohol or drug dependence or abuse, psychosis or severe organic illness.
Currently being treated in a similar treatment program.
Taking anxiolytics during the study (or in the case of taking them, changing drug or dose during the study).
Trial design
Treatments tested in this trial
- Cognitive behavioral therapy with in vivo exposure
- Cognitive behavorial therapy with in vivo exposure plus SYMPTOMS-JIT
Treatment groups
158 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov